# Vir Biotechnology, Inc.: financial statements, quarterly

VIR · Nasdaq · CIK 1706431 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vir.md) · [Financials](/companies/vir/financials.md) · [Filings](/companies/vir/filings.md) · [Insiders](/companies/vir/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/vir/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2.6](/filings/0001628280-24-044995.md) | [16.8 d](/filings/0001628280-26-010749.md) | [56.4](/filings/0001628280-25-023291.md) | [3.1](/filings/0001628280-25-038431.md) | [2.4](/filings/0001628280-25-049694.md) | [12.4 d](/filings/0001628280-26-010749.md) | [3.0](/filings/0001628280-25-023291.md) | [1.2](/filings/0001628280-25-038431.md) | [0.2](/filings/0001628280-25-049694.md) | [64.1 d](/filings/0001628280-26-010749.md) | [(0.0)](/filings/0001628280-26-031471.md) | [239](/filings/0001628280-26-053549.md) |
| Cost of revenue | $m | [0.0](/filings/0001628280-24-044995.md) | [0.8 d](/filings/0001628280-26-010749.md) | [0.1](/filings/0001628280-25-023291.md) | [0.1](/filings/0001628280-25-038431.md) | [0.1](/filings/0001628280-24-044995.md) | [0.7 d](/filings/0001628280-26-010749.md) | [0.0](/filings/0001628280-25-023291.md) | [0.0](/filings/0001628280-26-053549.md) | not reported | not reported | not reported | [0.0](/filings/0001628280-26-053549.md) |
| Research and development | $m | [145](/filings/0001628280-24-044995.md) | [109 d](/filings/0001628280-26-010749.md) | [100](/filings/0001628280-25-023291.md) | [105](/filings/0001628280-25-038431.md) | [195](/filings/0001628280-25-049694.md) | [106 d](/filings/0001628280-26-010749.md) | [119](/filings/0001628280-26-031471.md) | [97.5](/filings/0001628280-26-053549.md) | [151](/filings/0001628280-25-049694.md) | [88.3 d](/filings/0001628280-26-010749.md) | [109](/filings/0001628280-26-031471.md) | [135](/filings/0001628280-26-053549.md) |
| Selling, general and administrative | $m | [40.9](/filings/0001628280-24-044995.md) | [41.2 d](/filings/0001628280-26-010749.md) | [36.3](/filings/0001628280-25-023291.md) | [30.3](/filings/0001628280-25-038431.md) | [25.7](/filings/0001628280-25-049694.md) | [26.7 d](/filings/0001628280-26-010749.md) | [23.9](/filings/0001628280-26-031471.md) | [22.3](/filings/0001628280-26-053549.md) | [22.2](/filings/0001628280-25-049694.md) | [23.6 d](/filings/0001628280-26-010749.md) | [23.3](/filings/0001628280-26-031471.md) | [30.2](/filings/0001628280-26-053549.md) |
| Operating income | $m | [(187)](/filings/0001628280-24-044995.md) | [(139) d](/filings/0001628280-26-010749.md) | [(80.1)](/filings/0001628280-25-023291.md) | [(159)](/filings/0001628280-25-038431.md) | [(231)](/filings/0001628280-25-049694.md) | [(117) d](/filings/0001628280-26-010749.md) | [(140)](/filings/0001628280-26-031471.md) | [(118)](/filings/0001628280-26-053549.md) | [(173)](/filings/0001628280-25-049694.md) | [(47.9) d](/filings/0001628280-26-010749.md) | [(132)](/filings/0001628280-26-031471.md) | [73.5](/filings/0001628280-26-053549.md) |
| Income tax | $m | [(3.2)](/filings/0001628280-24-044995.md) | [(4.8) d](/filings/0001628280-26-010749.md) | [0.3](/filings/0001628280-25-023291.md) | [(1.5)](/filings/0001628280-25-038431.md) | [0.2](/filings/0001628280-25-049694.md) | [(0.1) d](/filings/0001628280-26-010749.md) | [0.0](/filings/0001628280-26-031471.md) | [0.2](/filings/0001628280-26-053549.md) | [0.2](/filings/0001628280-25-049694.md) | [(0.1) d](/filings/0001628280-26-010749.md) | [0.2](/filings/0001628280-26-031471.md) | [0.2](/filings/0001628280-26-053549.md) |
| Net income | $m | [(163)](/filings/0001628280-24-044995.md) | [(116) d](/filings/0001628280-26-010749.md) | [(65.3)](/filings/0001628280-25-023291.md) | [(138)](/filings/0001628280-25-038431.md) | [(214)](/filings/0001628280-25-049694.md) | [(105) d](/filings/0001628280-26-010749.md) | [(121)](/filings/0001628280-26-031471.md) | [(111)](/filings/0001628280-26-053549.md) | [(163)](/filings/0001628280-25-049694.md) | [(42.9) d](/filings/0001628280-26-010749.md) | [(126)](/filings/0001628280-26-031471.md) | [80.1](/filings/0001628280-26-053549.md) |
| Diluted EPS | $ per share | [(1.22)](/filings/0001628280-24-044995.md) | not reported | [(0.48)](/filings/0001628280-25-023291.md) | [(1.02)](/filings/0001628280-25-038431.md) | [(1.56)](/filings/0001628280-25-049694.md) | not reported | [(0.88)](/filings/0001628280-26-031471.md) | [(0.80)](/filings/0001628280-26-053549.md) | [(1.17)](/filings/0001628280-25-049694.md) | not reported | [(0.85)](/filings/0001628280-26-031471.md) | [0.47](/filings/0001628280-26-053549.md) |
| Basic EPS | $ per share | [(1.22)](/filings/0001628280-24-044995.md) | not reported | [(0.48)](/filings/0001628280-25-023291.md) | [(1.02)](/filings/0001628280-25-038431.md) | [(1.56)](/filings/0001628280-25-049694.md) | not reported | [(0.88)](/filings/0001628280-26-031471.md) | [(0.80)](/filings/0001628280-26-053549.md) | [(1.17)](/filings/0001628280-25-049694.md) | not reported | [(0.85)](/filings/0001628280-26-031471.md) | [0.48](/filings/0001628280-26-053549.md) |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [452](/filings/0001628280-24-044995.md) | [242](/filings/0001628280-26-010749.md) | [161](/filings/0001628280-25-023291.md) | [297](/filings/0001628280-25-038431.md) | [168](/filings/0001628280-25-049694.md) | [223](/filings/0001628280-26-010749.md) | [274](/filings/0001628280-26-031471.md) | [211](/filings/0001628280-26-053549.md) | [170](/filings/0001628280-25-049694.md) | [232](/filings/0001628280-26-053549.md) | [274](/filings/0001628280-26-031471.md) | [279](/filings/0001628280-26-053549.md) |
| Current assets | $m | [1,769](/filings/0001628280-23-036702.md) | [1,588](/filings/0001628280-25-008245.md) | [1,213](/filings/0001628280-24-020299.md) | [1,206](/filings/0001628280-24-034195.md) | [1,047](/filings/0001628280-24-044995.md) | [1,042](/filings/0001628280-26-010749.md) | [932](/filings/0001628280-25-023291.md) | [736](/filings/0001628280-25-038431.md) | [546](/filings/0001628280-25-049694.md) | [514](/filings/0001628280-26-053549.md) | [523](/filings/0001628280-26-031471.md) | [574](/filings/0001628280-26-053549.md) |
| Total assets | $m | [2,045](/filings/0001628280-23-036702.md) | [1,919](/filings/0001628280-25-008245.md) | [1,794](/filings/0001628280-24-020299.md) | [1,670](/filings/0001628280-24-034195.md) | [1,498](/filings/0001628280-24-044995.md) | [1,399](/filings/0001628280-26-010749.md) | [1,308](/filings/0001628280-25-023291.md) | [1,193](/filings/0001628280-25-038431.md) | [1,019](/filings/0001628280-25-049694.md) | [1,003](/filings/0001628280-26-053549.md) | [1,026](/filings/0001628280-26-031471.md) | [1,215](/filings/0001628280-26-053549.md) |
| Current liabilities | $m | [165](/filings/0001628280-23-036702.md) | [175](/filings/0001628280-25-008245.md) | [94.1](/filings/0001628280-24-020299.md) | [96.4](/filings/0001628280-24-034195.md) | [117](/filings/0001628280-24-044995.md) | [120](/filings/0001628280-26-010749.md) | [137](/filings/0001628280-25-023291.md) | [105](/filings/0001628280-25-038431.md) | [75.2](/filings/0001628280-25-049694.md) | [92.8](/filings/0001628280-26-053549.md) | [73.6](/filings/0001628280-26-031471.md) | [95.0](/filings/0001628280-26-053549.md) |
| Total liabilities | $m | [370](/filings/0001628280-23-036702.md) | [329](/filings/0001628280-25-008245.md) | [247](/filings/0001628280-24-020299.md) | [236](/filings/0001628280-24-034195.md) | [258](/filings/0001628280-24-044995.md) | [248](/filings/0001628280-26-010749.md) | [264](/filings/0001628280-25-023291.md) | [245](/filings/0001628280-25-038431.md) | [223](/filings/0001628280-25-049694.md) | [238](/filings/0001628280-26-053549.md) | [213](/filings/0001628280-26-031471.md) | [232](/filings/0001628280-26-053549.md) |
| Shareholders' equity | $m | [1,675](/filings/0001628280-24-044995.md) | [1,590](/filings/0001628280-25-049694.md) | [1,547](/filings/0001628280-25-038431.md) | [1,434](/filings/0001628280-25-049694.md) | [1,241](/filings/0001628280-25-049694.md) | [1,150](/filings/0001628280-26-053549.md) | [1,044](/filings/0001628280-26-053549.md) | [947](/filings/0001628280-26-053549.md) | [796](/filings/0001628280-25-049694.md) | [765](/filings/0001628280-26-053549.md) | [813](/filings/0001628280-26-053549.md) | [982](/filings/0001628280-26-053549.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest, us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(156) d](/filings/0001628280-24-044995.md) | [(108) d](/filings/0001628280-26-010749.md) | [(109)](/filings/0001628280-25-023291.md) | [(77.8) d](/filings/0001628280-25-038431.md) | [(171) d](/filings/0001628280-25-049694.md) | [(87.6) d](/filings/0001628280-26-010749.md) | [(78.1)](/filings/0001628280-26-031471.md) | [(120) d](/filings/0001628280-26-053549.md) | [(168) d](/filings/0001628280-25-049694.md) | [(25.9) d](/filings/0001628280-26-010749.md) | [(132)](/filings/0001628280-26-031471.md) | [123 d](/filings/0001628280-26-053549.md) |
| Capital expenditure | $m | [3.7 d](/filings/0001628280-24-044995.md) | [1.5 d](/filings/0001628280-26-010749.md) | [1.9](/filings/0001628280-25-023291.md) | [0.7 d](/filings/0001628280-25-038431.md) | [2.8 d](/filings/0001628280-25-049694.md) | [2.0 d](/filings/0001628280-26-010749.md) | [1.6](/filings/0001628280-26-031471.md) | [2.5 d](/filings/0001628280-26-053549.md) | [0.3 d](/filings/0001628280-25-049694.md) | [0.3 d](/filings/0001628280-26-010749.md) | [0.4](/filings/0001628280-26-031471.md) | [0.0 d](/filings/0001628280-26-053549.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [135](/filings/0001628280-23-036702.md) | [134](/filings/0001628280-24-020299.md) | [134](/filings/0001628280-24-034195.md) | [134](/filings/0001628280-24-044995.md) | [135](/filings/0001628280-25-023291.md) | [136](/filings/0001628280-25-038431.md) | [137](/filings/0001628280-25-049694.md) | [137](/filings/0001628280-26-031471.md) | [138](/filings/0001628280-26-053549.md) | [139](/filings/0001628280-25-049694.md) | [147](/filings/0001628280-26-031471.md) | [169](/filings/0001628280-26-053549.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 169,215,958 at 2026-07-29, from the cover of the [10-Q filed 2026-08-05](/filings/0001628280-26-053549.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.